LONDON (Alliance News) - e-Therapeutics PLC and C4X Discovery Holdings PLC on Tuesday announced a research collaboration to look into insights into Parkinson's disease.
The partnership, e-Therapeutics said, is to use its own drug discovery platform alongside C4X's genomics capabilities.
C4X said teams from both firms will use shared technology to identify identification strategies which it hopes will lead to new approaches to the treatment of Parkinson's.
Results generated from the collaboration will be jointly-owned by the two firms. Financial details of the agreement have not been disclosed.
e-Therapeutics Chief Executive Ray Barlow said: "We are delighted to be entering into this collaboration with C4XD, which has the ultimate ambition of discovering novel drugs for Parkinson's disease, a debilitating and progressive condition where there remains a significant unmet medical need for truly effective treatments."
C4X's Chief Strategy Officer Craig Fox said: "This collaboration not only demonstrates the potential of C4XD's drug discovery technologies but also highlights our desire to maximise the value from our novel genetic analysis by accessing complementary and synergistic proprietary technologies."
"This strategy will most effectively support our pursuit of licensable pre-clinical drug assets, such as the Orexin-1 receptor antagonist recently licensed to Indivior for up to USD294 million. We look forward to working with e-Therapeutics and to a successful outcome."
C4X shares were flat Tuesday at 108.00 pence each, while e-Therapeutics shares were also flat at 7.25p.
